The new study, led by the Institute for Molecular Medicine (IMM) and the National Institute of Aging in collaboration with the University of California, Irvine, and the University of California, San Diego, describes four vaccines designed to generate high levels of antibodies specific to various regions of pathological α-Synuclein.
January 10, 2022
· 3 min read